Who
Bruce Car
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Biohaven; Chief Scientific Officer, Agios Pharmaceuticals.
In numbers
- Trades disclosed
- 38
- Buys
- 1
- Sells
- 0
- Bought
- $1.0M
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 6 Jan 2020
- Last trade
- 27 Feb 2026
- Last filed
- 3 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 27 Feb 2026filed 3 Mar 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —4,750 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $24K2,381 at $9.93 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,750 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,750 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —4,750 at $0.00 | filing |
| 5 Jan 2026filed 7 Jan 2026 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $24K2,381 at $9.93 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,000 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code M | —4,750 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Code M | —4,750 at $0.00 | filing |
| 5 Jan 2025filed 7 Jan 2025 | BHVN BiohavenBiotechnology | SEC FORM 4 Code F | $90K2,331 at $38.64 | filing |
| 17 Jun 2024filed 20 Jun 2024 | BHVN BiohavenBiotechnology | SEC FORM 4 Bought | $1.0M30,000 at $33.58 | filing |
| 2 Jan 2024filed 4 Jan 2024 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —96,250 at $0.00 | filing |
| 2 Nov 2023filed 6 Nov 2023 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,750 at $0.00 | filing |
| 3 Oct 2022filed 5 Oct 2022 | BHVN Biohavenoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 1 Mar 2022filed 3 Mar 2022 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 1 Mar 2022filed 3 Mar 2022 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —41,000 at $0.00 | filing |
| 22 Feb 2022filed 23 Feb 2022 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $59K2,041 at $29.08 | filing |
News
Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target UpgradeBHVN · insidermonkey.com · 23 Oct 2026Biohaven's Troriluzole NDA Accepted For FDA Review; Decision In Q1 2027; Stock UpBHVN · rttnews.com · 22 Oct 2026Biohaven Stock Soars Nearly 30% After FDA Accepts Resubmitted Application for Rare Disease Drug VyglxiaBHVN · ibtimes.com.au · 22 Oct 2026
0 headlines in the last 90 days name Bruce Car; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.